Files
Download Full Text (499 KB)
Description
Acute cholecystitis affects approximately 200,000 patients in the United States every year and is the most common clinical indication for hepatobiliary scintigraphy. It can be diagnosed with CT, MRI, ultrasound, or composite clinical judgment, but hepatobiliary scintigraphy has been reported to have higher accuracy. Iminodiacetic agents are used in hepatobiliary imaging and have prompt hepatic uptake and excretion into the biliary system. Two agents currently approved by the FDA: Tc-99 m disofenin and Tc-99 m mebrofenin. During the COVID-19 pandemic from July to Sep 2021, there were supply chain disruptions which made sestamibi a potential substitute. This study is a retrospective analysis of those patients that used Tc-99 m sestamibi for hepatobiliary imaging and the diagnostic accuracy of those studies.
Publication Date
5-9-2025
Recommended Citation
Munavar Ali MA, Davenport M, Wale D, Otemuyiwa B, Viglianti B. Sestamibi as an alternative to mebrofenin for the diagnosis of acute cholecystitis: An alternative option during supply chain disruption. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1714